Company news
Incannex Healthcare Inc. (NASDAQ:IXHL) news
Incannex Healthcare Inc. news releases on 6ix. Latest, Oct 1, 2026: Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
Press releases & updates
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
October 1, 2026
Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
September 9, 2026
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
August 25, 2026
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
July 22, 2026
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
June 25, 2026
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
June 10, 2026
Incannex Announces Initiation of Research Coverage by Alliance Global Partners
June 8, 2026
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
May 14, 2026
Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough
May 7, 2026
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
April 22, 2026
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
March 26, 2026
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research
March 24, 2026
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development
March 17, 2026
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 16, 2026
Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes
March 11, 2026
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
March 11, 2026
Incannex Announces Reverse Stock Split
February 24, 2026
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026
February 18, 2026
Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board
January 29, 2026
Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program
January 22, 2026
Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards
January 15, 2026
Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026
January 14, 2026
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)
December 3, 2025
Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus
October 30, 2025
Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
October 22, 2025
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder
August 26, 2025
Incannex Healthcare Authorizes $20 Million Share Repurchase Program
August 22, 2025
Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea
August 8, 2025
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term
July 31, 2025
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X
July 30, 2025
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo
July 25, 2025
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch
June 24, 2025
Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X
June 18, 2025
Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy
June 17, 2025
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
June 12, 2025
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
June 3, 2025
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
May 29, 2025
Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results
May 28, 2025
Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution
May 20, 2025
Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants
May 16, 2025
Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates
May 15, 2025
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
May 14, 2025
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
April 3, 2025
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
March 7, 2025
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
February 13, 2025
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board
February 3, 2025
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea
January 22, 2025
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates
November 13, 2024
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
October 23, 2024
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
September 29, 2024